Wells, Athol U.
Jacob, Joseph
Sverzellati, Nicola
Cross, Gary
Barnett, Joseph
De Lauretis, Angelo
Antoniou, Katerina
Weycker, Derek
Atwood, Mark
Kirchgaessler, Klaus-Uwe
Cottin, Vincent
Article History
Received: 25 July 2023
Accepted: 30 October 2023
First Online: 18 January 2024
Declarations
:
: Athol U. Wells reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd. and Veracyte; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim and F. Hoffmann-La Roche, Ltd. Joseph Jacob has received payment or other financial remuneration from Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd., Gilead, GlaxoSmithKline, Microsoft Research, NHSX and Takeda unrelated to the submitted work. Joseph Jacob reports UK patent application numbers 2113765.8 and GB2211487.0 unrelated to the submitted work. Joseph Jacob is supported by a Wellcome Trust Clinical Research Career Development Fellowship (209553/Z/17/Z) and the NIHR UCLH Biomedical Research Centre. Nicola Sverzellati has received grants from Chiesi and Coreline; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Boehringer Ingelheim and Chiesi; and support for attending meetings and/or travel from Bracco. Gary Cross, Joseph Barnett and Angelo De Lauretis declare no conflicts of interest relevant to the current publication. Katerina Antoniou reports consulting fees from Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd. and GlaxoSmithKline; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, F. Hoffmann-La Roche, Ltd., GlaxoSmithKline and Menarini; participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd. and GlaxoSmithKline. Derek Weycker and Mark Atwood are employees of Policy Analysis Inc. (PAI). Klaus-Uwe Kirchgaessler is a former employee and shareholder of F. Hoffmann-La Roche, Ltd. Vincent Cottin reports unrestricted grants paid to his institution from Boehringer Ingelheim; consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene/BMS, CSL Behring, F. Hoffmann-La Roche, Ltd., Ferrer/United Therapeutics, GlaxoSmithKline, Pliant, Pure Tech, RedX, Sanofi and Shionogi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd. and Ferrer/United Therapeutics; support for attending meetings and/or travel from Boehringer Ingelheim and F. Hoffmann-La Roche, Ltd.; participation on a Data Safety Monitoring Board or Advisory Board for Galapagos and Galecto; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with FibroGen.
: No prospective data were collected during this analysis; therefore, ethical approval was not required.
: Not applicable.